Gilead Sciences acquires Arcellx

Gilead Sciences has agreed to acquire Arcellx in a transaction valued at approximately $7.8 billion, marking a significant move to expand its portfolio in cell therapies targeted at multiple myeloma. This strategic acquisition will deepen Gilead’s investment in the development and commercialization of anitocabtagene autoleucel (anito-cel), an investigational CAR T-cell treatment for patients afflicted with relapsed or refractory multiple myeloma.

The financial specifics of the deal involve Gilead offering $115 per Arcellx share in cash and an additional $5 per share through a contingent value right, conditional on cumulative global sales of anito-cel reaching $6 billion by 2029. This represents a 68% premium over Arcellx's recent stock performance. Gilead plans to finalize the acquisition via a tender offer and a subsequent merger by the second quarter of 2026. If approved, the deal is expected to contribute positively to Gilead's earnings per share starting in 2028.

The acquisition builds on Gilead's existing collaboration with Arcellx, facilitated through its Kite subsidiary, which has been pivotal in the joint development and commercialization of anito-cel. The drug, under evaluation for its potential as a fourth-line treatment for multiple myeloma, is backed by Phase I and Phase II trial data and is pending FDA review with a decision expected by December 2026. Daniel O’Day, Gilead’s CEO, emphasized the therapeutic potential of anito-cel, noting its potential to become integral in treating multiple myeloma and possibly extending its application to earlier stages of treatment.

In acquiring Arcellx, Gilead gains access to its proprietary D-Domain CAR platform, which exhibits enhanced specificity and affinity for target-binding. This technology offers potential advancements in both CAR T-cell and bispecific therapies, positioning Gilead to enhance its in vivo cell therapy development and strengthen its oncology pipeline. Arcellx CEO Rami Elghandour highlighted the synergy with Gilead, asserting that Kite’s expertise will ensure broader patient access to anito-cel.

The acquisition occurs amidst an evolving landscape in biotechnology, where innovative treatments are crucial for addressing diseases like multiple myeloma that have seen limited success with conventional therapies. The move underscores a broader industry trend of established companies expanding capabilities through strategic acquisitions to address unmet medical needs. As regulatory reviews proceed, the focus will be on the successful integration and commercial scaling of anito-cel, potentially reshaping therapeutic approaches to multiple myeloma.